文献速递泌尿系感染前列腺增生与排尿功能障碍

中东和北非慢性前列腺炎/慢性盆腔疼痛综合征男性的临床表型与多模式治疗:治疗结局及临床改善预测因素

Clinical Phenotyping and Multimodal Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome From the Middle East and North Africa: Determining Treatment Outcomes and Predictors of Clinical Improvement.
PubMed 文献 · Urology · 2022-05-06

在卡塔尔多哈开展回顾性研究,纳入中东和北非CP/CPPS患者,用UPOINT表型系统分类并指导多模式治疗。治疗3个月后NIH-CPSI平均降低8.21分(P < .001),66.2%患者达到临床改善;临床改善与疼痛程度、初始NIH-CPSI、阳性UPOINT域数及治疗种数均无显著关联。

要点

  • UPOINT表型指导的多模式治疗3个月后NIH-CPSI平均降低8.21分(P < .001)。
  • 66.2%患者治疗3个月后NIH-CPSI总分至少降低6分,达到临床改善。
  • 临床改善与疼痛程度、初始NIH-CPSI、阳性UPOINT域数及治疗种数均无显著关联。

核心结论

  • UPOINT表型指导的治疗与CP/CPPS患者的重要改善相关,治疗反应似乎与年龄或族裔无关,临床改善也不由初始疾病范围与严重程度或治疗种数预测。

研究设计与样本

  • 在卡塔尔多哈开展的回顾性研究,纳入来自中东和北非的CP/CPPS患者,采用UPOINT表型系统分类并指导多模式治疗。
  • 初始及治疗3个月后计算NIH-CPSI评分,并评估临床改善的预测因素。

主要发现

  • 治疗3个月后总NIH-CPSI平均降低8.21分(P < .001)。
  • 66.2%的患者在治疗3个月后总NIH-CPSI评分至少降低6分,达到临床改善。
  • 临床改善与疼痛程度无显著关联(ORa = 1.198,95%CI 0.392-3.662,P = .751)。
  • 临床改善与初始总NIH-CPSI无显著关联(ORa = 0.983,95%CI 0.886-1.089,P = .738)。
  • 临床改善与阳性UPOINT域数无显著关联(ORa = 0.871,95%CI 0.451-1.681,P = .681),与处方治疗种数也无显著关联(ORa = 1.118,95%CI 0.699-1.789,P = .641)。

临床怎么用

  • 作者认为UPOINT表型指导的治疗与CP/CPPS患者的重要改善相关,治疗反应似乎与年龄或族裔无关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of UPOINT based multimodal treatment on patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and determine factors that could be associated with clinical improvement. METHODS: A retrospective study was conducted in Doha, Qatar including patients with CP/CPPS from the Middle East and North Africa. The UPOINT phenotyping system was used to classify patients and guide their multimodal therapy. NIH-CPSI scores were computed initially and after 3 months of treatment, and predictors of clinical improvement were assessed. RESULTS: The total NIH-CPSI improved significantly with a mean reduction of 8.21 after 3 months of treatment (P < .001). 66.2% of patients had a clinical improvement demonstrated as a total NIH-CPSI score reduction by at least 6 points after 3 months of treatment. No significant association was found between clinical improvement, and extent of pain (ORa = 1.198, 95% CI 0.392-3.662, P = .751), initial total NIH-CPSI (ORa = 0.983, 95% CI 0.886-1.089, P = .738), number of positive UPOINT domains (ORa = 0.871, 95% CI 0.451-1.681, P = .681), and number of prescribed therapies (ORa = 1.118, 95% CI 0.699-1.789, P = .641). CONCLUSION: UPOINT phenotyping and directed therapy is associated with an important improvement in the CP/CPPS. Therapeutic response does not appear to related to age or ethnicity. Clinical improvement is also not predicted by initial extent and severity of the disease, whether relating to NIH-CPSI or the number of positive UPOINT phenotypes, neither to the number of therapies involved in the multimodal treatment strategy.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Majzoub A, Mahdi M, Khalil I, et al. Clinical Phenotyping and Multimodal Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome From the Middle East and North Africa: Determining Treatment Outcomes and Predictors of Clinical Improvement. Urology. 2022. PMID: 35533765. doi:10.1016/j.urology.2022.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。